News

SSWL shines on bagging export orders for over 6,000 wheels for US Truck and Caravan Trailer Market

Steel Strips Wheels is currently trading at Rs. 427.95, up by 12.15 points or 2.92% from its previous closing of Rs. 415.80 on the BSE.

The scrip opened at Rs. 427.95 and has touched a high and low of Rs. 429.40 and Rs. 417.35 respectively. So far 1719 shares were traded on the counter.

The BSE group ‘B’ stock of face value Rs. 10 has touched a 52 week high of Rs. 798.00 on 20-Sep-2019 and a 52 week low of Rs. 317.35 on 20-May-2020.

Last one week high and low of the scrip stood at Rs. 429.40 and Rs. 393.30 respectively. The current market cap of the company is Rs. 662.56 crore.

The promoters holding in the company stood at 62.85%, while Institutions and Non-Institutions held 0.98% and 36.17% respectively.

Steel Strips Wheels (SSWL) has bagged firm export orders for over 6,000 wheels for US Truck and Caravan Trailer Market to be executed in August from its Chennai plant. Similar orders are expected in times to come from other regular customers as the market regains normalcy. This will support further ramping up of production at Chennai Steel Wheels plant.

SSWL is a part of the Steel Strips Group, headquartered in Chandigarh. It is engaged in the manufacturing of single piece steel wheel rims in the range of 10 to 30 inches for scooters, passenger cars, utility vehicles and tractors. It supplies rims to almost all major manufacturers of two wheelers, three wheelers, four wheelers, tractors and heavy commercial vehicle.

Read More
News

INOX Leisure surges despite reporting consolidated net loss of Rs 74 crore in Q1

Inox Leisure is currently trading at Rs. 238.30, up by 3.95 points or 1.69% from its previous closing of Rs. 234.35 on the BSE.
 
The scrip opened at Rs. 234.00 and has touched a high and low of Rs. 239.50 and Rs. 231.00 respectively. So far 8518 shares were traded on the counter.
 
The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 510.80 on 25-Feb-2020 and a 52 week low of Rs. 158.20 on 19-May-2020.
 
Last one week high and low of the scrip stood at Rs. 245.00 and Rs. 228.55 respectively. The current market cap of the company is Rs. 2451.10 crore.
 
The promoters holding in the company stood at 51.89%, while Institutions and Non-Institutions held 29.87% and 18.04% respectively.
 
The company has reported net loss of Rs 73.65 crore for the first quarter ended June 30, 2020 as against net profit of Rs 26.98 crore for the same quarter in the previous year. Total income of the company decreased 99.40% at Rs 2.96 crore for Q1FY21 as compared Rs 496.11 crore for the corresponding quarter previous year.
 
On the consolidated basis, the company has reported net loss attributable to owners at Rs 73.64 crore for the quarter under review as against net profit of Rs 27.01 crore for the same quarter in the previous year. Total income of the company decreased by 99.40% at Rs 2.97 crore for Q1FY21 as compared Rs 496.13 crore for the corresponding quarter previous year.
Read More
News

Apollo Tyres falls on reporting consolidated net loss of Rs 134 crore in Q1

Apollo Tyres is currently trading at Rs. 113.75, down by 2.05 points or 1.77% from its previous closing of Rs. 115.80 on the BSE.
The scrip opened at Rs. 115.60 and has touched a high and low of Rs. 115.60 and Rs. 111.00 respectively. So far 434913 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 196.70 on 01-Nov-2019 and a 52 week low of Rs. 73.55 on 24-Mar-2020.
Last one week high and low of the scrip stood at Rs. 117.70 and Rs. 107.05 respectively. The current market cap of the company is Rs. 6472.75 crore.
The promoters holding in the company stood at 41.65%, while Institutions and Non-Institutions held 39.62% and 18.73% respectively.
The company has reported net loss of Rs 53.65 crore for the first quarter ended June 30, 2020 as against net profit of Rs 149.86 crore for the same quarter in the previous year. Total income of the company decreased 42.80% at Rs 1787.73 crore for Q1FY21 as compared Rs 3125.17 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported net loss of Rs 134.58 crore for the quarter under review as against net profit of Rs 141.60 crore for the same quarter in the previous year. Total income of the company decreased by 33.46% at Rs 2900.28 crore for Q1FY21 as compared Rs 4358.79 crore for the corresponding quarter previous year.

 

Read More
News

Indoco Remedies surges on getting USFDA’s nod for Olanzapine Tablets

Indoco Remedies is currently trading at Rs. 236.95, up by 2.80 points or 1.20% from its previous closing of Rs. 234.15 on the BSE.

The scrip opened at Rs. 236.80 and has touched a high and low of Rs. 240.00 and Rs. 232.35 respectively. So far 9717 shares were traded on the counter.

The BSE group ‘B’ stock of face value Rs. 2 has touched a 52 week high of Rs. 285.00 on 13-Apr-2020 and a 52 week low of Rs. 133.10 on 11-Oct-2019.

Last one week high and low of the scrip stood at Rs. 255.95 and Rs. 208.00 respectively. The current market cap of the company is Rs. 2190.87 crore.

The promoters holding in the company stood at 58.69%, while Institutions and Non-Institutions held 16.54% and 24.77% respectively.

Indoco Remedies has received approval from US Food and Drug Administration (USFDA) for its ANDA for Olanzapine Tablets USP 2.5mg, 5mg, 7.5 mg, 10mg, 15mg and 20 mg. The products are therapeutically equivalent to the Reference Listed Drug ‘Zyprexa’ of Eli Lilly.

Olanzapine is indicated for the treatment of schizophrenia and bipolar disorder. The drug may also be used in combination with other medication to treat depression and certain mental conditions. The US market size of Olanzapine Tablets is $65 million.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Read More
stock

DLF gains despite reporting consolidated net loss of Rs 71 crore in Q1

DLF is currently trading at Rs. 143.40, up by 1.00 points or 0.70% from its previous closing of Rs. 142.40 on the BSE.
 
The scrip opened at Rs. 140.00 and has touched a high and low of Rs. 147.40 and Rs. 140.00 respectively. So far 491966 shares were traded on the counter.
 
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 266.65 on 01-Feb-2020 and a 52 week low of Rs. 114.50 on 25-Mar-2020.
 
Last one week high and low of the scrip stood at Rs. 147.40 and Rs. 138.10 respectively. The current market cap of the company is Rs. 35471.22 crore.
 
The promoters holding in the company stood at 74.95%, while Institutions and Non-Institutions held 20.30% and 4.75% respectively.
 
The company has reported net loss of Rs 40.00 crore for the first quarter ended June 30, 2020 as against net profit of Rs 782.65 crore for the same quarter in the previous year. Total income of the company decreased 39.52% at Rs 385.83 crore for Q1FY21 as compared Rs 637.97 crore for the corresponding quarter previous year.
 
On the consolidated basis, the company has reported net loss attributable to owners at Rs 70.65 crore for the quarter under review as against net profit of Rs 414.72 crore for the same quarter in the previous year. Total income of the company decreased by 58.01% at Rs 646.98 crore for Q1FY21 as compared Rs 1540.95 crore for the corresponding quarter previous year.
Read More
News

Alkem Laboratories shines on launching Favipiravir for COVID-19 treatment

Alkem Laboratories is currently trading at Rs. 2955.00, up by 113.00 points or 3.98% from its previous closing of Rs. 2842.00 on the BSE.

The scrip opened at Rs. 2900.00 and has touched a high and low of Rs. 2972.60 and Rs. 2900.00 respectively. So far 4295 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 2975.65 on 04-Aug-2020 and a 52 week low of Rs. 1,682.10 on 07-Aug-2019.

Last one week high and low of the scrip stood at Rs. 2975.65 and Rs. 2538.20 respectively. The current market cap of the company is Rs. 33980.37 crore.

The promoters holding in the company stood at 62.43%, while Institutions and Non-Institutions held 15.52% and 21.80% respectively.

Alkem Laboratories has launched Favipiravir under the brand name ‘Alfluenza’ in India for the management of mild to moderate cases of COVID-19. Favipiravir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Read More
News

Vivimed Labs touches roof on receiving export order for supply of Favulous tablets

Vivimed Labs is locked at upper circuit limit of Rs. 12.84, up by 0.61 points or 4.99% from its previous closing of Rs. 12.23 on the BSE.

The scrip opened at Rs. 12.84 and has touched a high and low of Rs. 12.84 and Rs. 12.84 respectively. So far shares were traded on the counter.

The BSE group ‘B’ stock of face value Rs. 2 has touched a 52 week high of Rs. 19.00 on 23-Sep-2019 and a 52 week low of Rs. 6.50 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 12.84 and Rs. 10.06 respectively. The current market cap of the company is Rs. 101.40 crore.

The promoters holding in the company stood at 32.79%, while Institutions and Non-Institutions held 3.56% and 63.53% respectively.

Vivimed Labs has received export order for supply of ‘Favulous’ tablets 200 mg (Favipiravir). Favulous tablets 200 mg (Favipiravir) is used for the treatment of mild to moderate cases of Covid-19. Favipiravir is the only oral antiviral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid19 disease. The initial Export order value is worth over Rs 100 Million. The company expects to receive further repeat orders during the Year.

The company is launching Favulous at an economical price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with company’s continuous efforts to support world’s pandemic response. The company will work closely with the various governments and medical community to ensure availability of Favulous to patients across the world.

Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.

Read More
News

CreditAccess Grameen gains despite reporting 25% fall in Q1 consolidated net profit

CreditAccess Grameen is currently trading at Rs. 556.20, up by 7.80 points or 1.42% from its previous closing of Rs. 548.40 on the BSE.

The scrip opened at Rs. 551.55 and has touched a high and low of Rs. 566.00 and Rs. 543.30 respectively. So far 8996 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 1000.80 on 20-Feb-2020 and a 52 week low of Rs. 305.75 on 07-Apr-2020.

Last one week high and low of the scrip stood at Rs. 566.00 and Rs. 500.00 respectively. The current market cap of the company is Rs. 8022.13 crore.

The promoters holding in the company stood at 79.91%, while Institutions and Non-Institutions held 14.56% and 5.53% respectively.

CreditAccess Grameen has reported 33.63% fall in its net profit of Rs 63.60 crore for the quarter ended June 30, 2020 as against Rs 95.83 crore for the same quarter in the previous year. However, total income of the company increased 35.57% at Rs 510.68 crore for Q1FY21 as compared Rs 376.70 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported 24.87% fall in its net profit attributable to owners at Rs 72.00 crore for the quarter ended June 30, 2020 as against Rs 95.83 crore for the same quarter in the previous year. However, total income of the company increased by 64.55% at Rs 619.87 crore for Q1FY21 as compared Rs 376.70 crore for the corresponding quarter previous year.

Read More
News

Godrej Consumer Products slips on reporting marginal fall in Q1

Godrej Consumer Products is currently trading at Rs. 681.50, down by 10.75 points or 1.55% from its previous closing of Rs. 692.25 on the BSE.

The scrip opened at Rs. 692.10 and has touched a high and low of Rs. 694.55 and Rs. 672.95 respectively. So far 59800 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 771.75 on 16-Jan-2020 and a 52 week low of Rs. 425.10 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 708.50 and Rs. 672.45 respectively. The current market cap of the company is Rs. 69682.11 crore.

The promoters holding in the company stood at 63.24%, while Institutions and Non-Institutions held 29.98% and 6.78% respectively.

Godrej Consumer Products has reported 13.16% rise in its net profit of Rs 271.66 crore for the quarter ended June 30, 2020 as against net profit of Rs 240.06 crore for the same quarter in the previous year. Total income of the company increased 5.08% at Rs 1402.84 crore for Q1FY21 as compared Rs 1335.00 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported 3.12% fall in its net profit attributable to owners at Rs 394.88 crore for the quarter ended June 30, 2020 as against net profit of Rs 407.60 crore for the same quarter in the previous year. Total income of the company decreased by 0.89% at Rs 2349.11 crore for Q1FY21 as compared Rs 2370.14 crore for the corresponding quarter previous year.

Read More
News

Sun Pharma rises on launching FluGuard in India at Rs 35 per tablet

Sun Pharmaceutical Industries is currently trading at Rs. 532.50, up by 4.00 points or 0.76% from its previous closing of Rs. 528.50 on the BSE.

The scrip opened at Rs. 536.35 and has touched a high and low of Rs. 537.70 and Rs. 530.30 respectively. So far 195543 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 540.75 on 31-Jul-2020 and a 52 week low of Rs. 315.20 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 540.75 and Rs. 487.65 respectively. The current market cap of the company is Rs. 128004.52 crore.

The promoters holding in the company stood at 54.69%, while Institutions and Non-Institutions held 32.81% and 12.50% respectively.

Sun Pharmaceutical Industries has launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

The company will work closely with the government and medical community to ensure availability of FluGuard to patients across the country. The stocks of FluGuard will be available in the market from this week.

Sun Pharma is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Read More